Cargando…
Nanopharmaceutical Approach for Enhanced Anti-cancer Activity of Betulinic Acid in Lung-cancer Treatment via Activation of PARP: Interaction with DNA as a Target: -Anti-cancer Potential of Nano-betulinic Acid in Lung Cancer-
OBJECTIVES: This study examined the relative efficacies of a derivative of betulinic acid (dBA) and its poly (lactide- co-glycolide) (PLGA) nano-encapsulated form in A549 lung cancer cells in vivo and in co-mutagen [sodium arsenite (SA) + benzo]undefined[a]pyrene (BaP)]-induced lung cancer in mice i...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
KOREAN PHARMACOPUNCTURE INSTITUTE
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887750/ https://www.ncbi.nlm.nih.gov/pubmed/27280048 http://dx.doi.org/10.3831/KPI.2016.19.005 |
_version_ | 1782434773626519552 |
---|---|
author | Das, Jayeeta Samadder, Asmita Das, Sreemanti Paul, Avijit Khuda-Bukhsh, Anisur Rahman |
author_facet | Das, Jayeeta Samadder, Asmita Das, Sreemanti Paul, Avijit Khuda-Bukhsh, Anisur Rahman |
author_sort | Das, Jayeeta |
collection | PubMed |
description | OBJECTIVES: This study examined the relative efficacies of a derivative of betulinic acid (dBA) and its poly (lactide- co-glycolide) (PLGA) nano-encapsulated form in A549 lung cancer cells in vivo and in co-mutagen [sodium arsenite (SA) + benzo]undefined[a]pyrene (BaP)]-induced lung cancer in mice in vivo. METHODS: dBA was loaded with PLGA nanoparticles by using the standard solvent displacement method. The sizes and morphologies of nano-dBA (NdBA) were determined by using transmission electron microscopy (TEM), and their intracellular localization was verified by using confocal microscopy. The binding and interaction of NdBA with calf thymus deoxyribonucleic acid (CT-DNA) as a target were analyzed by using conventional circular dichroism (CD) and melting temperature (Tm) profile data. Apoptotic signalling cascades in vitro and in vivo were studied by using an enzyme-linked immunosorbent assay (ELISA); the ability of NdBA to cross the blood-brain barrier (BBB) was also examined. The stage of cell cycle arrest was confirmed by using a fluorescence-activated cell-sorting (FACS) data analysis. RESULTS: The average size of the nanoparticles was ~ 110 nm. Confocal microscopy images confirmed the presence of NdBA in the cellular cytoplasm. The bio-physical properties of dBA and NdBA ascertained from the CD and the Tm profiles revealed that NdBA had greater interaction with the target DNA than dBA did. Both dBA and NdBA arrested cell proliferation at G0/G1, NdBA showing the greater effect. NdBA also induced a greater degree of cytotoxicity in A549 cells, but it had an insignificant cytotoxic effect in normal L6 cells. The results of flow cytometric, cytogenetial and histopathological studies in mice revealed that NdBA caused less nuclear condensation and DNA damage than dBA did. TEM images showed the presence of NdBA in brain samples of NdBA fed mice, indicating its ability to cross the BBB. CONCLUSION: Thus, compared to dBA, NdBA appears to have greater chemoprotective potential against lung cancer. |
format | Online Article Text |
id | pubmed-4887750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | KOREAN PHARMACOPUNCTURE INSTITUTE |
record_format | MEDLINE/PubMed |
spelling | pubmed-48877502016-06-08 Nanopharmaceutical Approach for Enhanced Anti-cancer Activity of Betulinic Acid in Lung-cancer Treatment via Activation of PARP: Interaction with DNA as a Target: -Anti-cancer Potential of Nano-betulinic Acid in Lung Cancer- Das, Jayeeta Samadder, Asmita Das, Sreemanti Paul, Avijit Khuda-Bukhsh, Anisur Rahman J Pharmacopuncture Original Article OBJECTIVES: This study examined the relative efficacies of a derivative of betulinic acid (dBA) and its poly (lactide- co-glycolide) (PLGA) nano-encapsulated form in A549 lung cancer cells in vivo and in co-mutagen [sodium arsenite (SA) + benzo]undefined[a]pyrene (BaP)]-induced lung cancer in mice in vivo. METHODS: dBA was loaded with PLGA nanoparticles by using the standard solvent displacement method. The sizes and morphologies of nano-dBA (NdBA) were determined by using transmission electron microscopy (TEM), and their intracellular localization was verified by using confocal microscopy. The binding and interaction of NdBA with calf thymus deoxyribonucleic acid (CT-DNA) as a target were analyzed by using conventional circular dichroism (CD) and melting temperature (Tm) profile data. Apoptotic signalling cascades in vitro and in vivo were studied by using an enzyme-linked immunosorbent assay (ELISA); the ability of NdBA to cross the blood-brain barrier (BBB) was also examined. The stage of cell cycle arrest was confirmed by using a fluorescence-activated cell-sorting (FACS) data analysis. RESULTS: The average size of the nanoparticles was ~ 110 nm. Confocal microscopy images confirmed the presence of NdBA in the cellular cytoplasm. The bio-physical properties of dBA and NdBA ascertained from the CD and the Tm profiles revealed that NdBA had greater interaction with the target DNA than dBA did. Both dBA and NdBA arrested cell proliferation at G0/G1, NdBA showing the greater effect. NdBA also induced a greater degree of cytotoxicity in A549 cells, but it had an insignificant cytotoxic effect in normal L6 cells. The results of flow cytometric, cytogenetial and histopathological studies in mice revealed that NdBA caused less nuclear condensation and DNA damage than dBA did. TEM images showed the presence of NdBA in brain samples of NdBA fed mice, indicating its ability to cross the BBB. CONCLUSION: Thus, compared to dBA, NdBA appears to have greater chemoprotective potential against lung cancer. KOREAN PHARMACOPUNCTURE INSTITUTE 2016-03 /pmc/articles/PMC4887750/ /pubmed/27280048 http://dx.doi.org/10.3831/KPI.2016.19.005 Text en Copyright ©2016, KOREAN PHARMACOPUNCTURE INSTITUTE http://creativecommons.org/licenses/by-nc/3.0/ This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Das, Jayeeta Samadder, Asmita Das, Sreemanti Paul, Avijit Khuda-Bukhsh, Anisur Rahman Nanopharmaceutical Approach for Enhanced Anti-cancer Activity of Betulinic Acid in Lung-cancer Treatment via Activation of PARP: Interaction with DNA as a Target: -Anti-cancer Potential of Nano-betulinic Acid in Lung Cancer- |
title | Nanopharmaceutical Approach for Enhanced Anti-cancer Activity of Betulinic Acid in Lung-cancer Treatment via Activation of PARP: Interaction with DNA as a Target: -Anti-cancer Potential of Nano-betulinic Acid in Lung Cancer- |
title_full | Nanopharmaceutical Approach for Enhanced Anti-cancer Activity of Betulinic Acid in Lung-cancer Treatment via Activation of PARP: Interaction with DNA as a Target: -Anti-cancer Potential of Nano-betulinic Acid in Lung Cancer- |
title_fullStr | Nanopharmaceutical Approach for Enhanced Anti-cancer Activity of Betulinic Acid in Lung-cancer Treatment via Activation of PARP: Interaction with DNA as a Target: -Anti-cancer Potential of Nano-betulinic Acid in Lung Cancer- |
title_full_unstemmed | Nanopharmaceutical Approach for Enhanced Anti-cancer Activity of Betulinic Acid in Lung-cancer Treatment via Activation of PARP: Interaction with DNA as a Target: -Anti-cancer Potential of Nano-betulinic Acid in Lung Cancer- |
title_short | Nanopharmaceutical Approach for Enhanced Anti-cancer Activity of Betulinic Acid in Lung-cancer Treatment via Activation of PARP: Interaction with DNA as a Target: -Anti-cancer Potential of Nano-betulinic Acid in Lung Cancer- |
title_sort | nanopharmaceutical approach for enhanced anti-cancer activity of betulinic acid in lung-cancer treatment via activation of parp: interaction with dna as a target: -anti-cancer potential of nano-betulinic acid in lung cancer- |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887750/ https://www.ncbi.nlm.nih.gov/pubmed/27280048 http://dx.doi.org/10.3831/KPI.2016.19.005 |
work_keys_str_mv | AT dasjayeeta nanopharmaceuticalapproachforenhancedanticanceractivityofbetulinicacidinlungcancertreatmentviaactivationofparpinteractionwithdnaasatargetanticancerpotentialofnanobetulinicacidinlungcancer AT samadderasmita nanopharmaceuticalapproachforenhancedanticanceractivityofbetulinicacidinlungcancertreatmentviaactivationofparpinteractionwithdnaasatargetanticancerpotentialofnanobetulinicacidinlungcancer AT dassreemanti nanopharmaceuticalapproachforenhancedanticanceractivityofbetulinicacidinlungcancertreatmentviaactivationofparpinteractionwithdnaasatargetanticancerpotentialofnanobetulinicacidinlungcancer AT paulavijit nanopharmaceuticalapproachforenhancedanticanceractivityofbetulinicacidinlungcancertreatmentviaactivationofparpinteractionwithdnaasatargetanticancerpotentialofnanobetulinicacidinlungcancer AT khudabukhshanisurrahman nanopharmaceuticalapproachforenhancedanticanceractivityofbetulinicacidinlungcancertreatmentviaactivationofparpinteractionwithdnaasatargetanticancerpotentialofnanobetulinicacidinlungcancer |